Mifepristone in Children With Refractory Cushing's Disease
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the
effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in
children with refractory Cushing's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Corcept Therapeutics
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)